AUTHOR INDEX

(BR) = Book reviewer; (C) = commentary; (E) = editorial; (L) = letter to the editor; (S) = supplement.

Abbott, M., 1233 (C)
Abdullah, A.S.M., 1731
Abroms, L., 852
Ackermann, K., 797
Acosta, M.C., 550
d'Acremont, M., 1302
Adams, C., 12 (S2), 19 (S2), 28 (S2)
Ádány, R., 536
Agrawal, A., 1709
Alati, R., 643, 872 (L)
Allen, D., 1584
Allsop, S., 417 (BR), 1071 (C)
Al-Tayyib, A., 1432
Alvarez, F.J., 1373
Amass, L., 1090
Ameratunga, S., 605
Amundsen, E.J., 1453
Andersen, M.R., 379
Anderson, P., 1070 (C), 1751 (E)
Anglin, M.D., 1131
Angrist, B., 32 (S1)
Annon, J., 1131
Annon, J.J., 1090
Anstey, K.J., 1280, 1291
Anzai, Y., 19, 30 (C)
Armstrong, M.A., 30 (C)
Asbridge, M., 1340
Aveyard, P., 107

Babcock, D., 1090
Babor, T.F., 3 (E), 579 (E), 581 (E)
Baca, C.T., 1823
Bachman, J.G., 512
Bailey, P., 1 (S2)
Baker, A., 367
Baker, S., 32 (S1), 43 (S1)
Bammer, G., 636
Banbery, J., 1860
Barrio, G., 981
Barrowclough, C., 304, 500
Bauld, L., 12 (S2), 19 (S2), 28 (S2), 36 (S2), 46 (S2), 59 (S2)
Bearn, J., 495, 1374
Bechara, A., 1302
Beck, J.C., 731 (E)
Bellés, A., 1166
Benegal, V., 1051
Bennett, J., 1370 (L)
Beranuy, M., 1166
Berger, P., 68 (S1)
Berger, S.P., 58 (S1)
Berglund, M., 742, 1376
Berlin, I., 247
Bernards, S., 755
Bigelow, G.E., 1496
Bischof, G., 405
Blanken, P., 89
Blaszczynski, A., 566 (BR), 1230 (C)
Bloch, D.A., 1 (S1), 12 (S1), 58 (S1), 68 (S1), 91 (S1), 102 (S1)
Bloomfield, K., 1770
Blows, S., 605
Bobak, M., 883 (E)
Bobova, L., 953
Bond, J., 1840
Bor, W., 643, 872 (L)
Bot, S.M., 1270
Boudreau, B., 525
Brady, M., 1030 (BR)
Brandon, K.O., 439 (C)
Brandon, T.H., 439 (C)
Brasser, S.M., 1496
Braunstein, D., 43 (S1)
Brearley, R., 1860
Breland, A.B., 550
Brennan, P.L., 777
Bricker, J.B., 379
Brigham, G., 1090
van den Brink, W., 89
Brucks, M., 1537
Brugal, M.T., 981
Brunelle, E., 1377
Buchan, B., 1090
Buchhalter, A.R., 550
Bucholz, K.K., 1709
Burns, L., 787
Butler, C., 1175

Cacciola, J., 447
Camacho, L.A.B., 489
Carlin, J.B., 1518
Carlini, E.A., 897
Carpenter, C.M., 837
Carpenter, M.J., 257 (L), 1074
Carpentier, C., 884 (E), 1560
Carpentier, P.J., 1868
Carr, V.J., 367
Carroll, K.M., 267 (E)
Casadonte, P., 43 (S1)
Casswell, S., 258 (L), 971, 1069 (C)
Caulkins, J.P., 928 (C)
Chaloupka, F., 1876
Chaloupka, F.J., 1394 (E)
Chapman, S., 701
Charnaud, B., 1741 (L)
Chau, K.V., 1003
Cheater, F., 12 (S2)
Chen, H., 737
Chen, R., 852
Cheng, K.K., 107
Cherpitel, C.J., 1840
Chesterman, J., 36 (S2), 46 (S2), 59 (S2)
Chikritzhs, T., 1625, 1885 (L)
Chou, P.S., 281, 296 (C)
Choudhary, I., 990
Christensen, H., 1280, 1291
Ciraulo, A.M., 12 (S1), 23 (S1)
Ciraulo, D., 91 (S1)
Ciraulo, D.A., 12 (S1), 23 (S1), 102 (S1)
Claire, M., 367
Clapp, J.D., 327
Clark, N.C., 197
Clough, A.R., 346
Coffey, C., 1518
Cohen, M.H., 990
Coleman, F.S., 68 (S1)
Coleman, T., 12 (S2), 19 (S2), 28 (S2), 70 (S2), 84 (S2)
Collins, L., 459, 908, 930 (C)
Collins, R.L., 235
Colmant, M., 1302
Conger, R.D., 441 (C)
Connolly, G.N., 837
Connor, J., 605
Conroy, E., 908
Constable, P., 367
Cook, C.C.H., 1555 (L)
Cook, J.A., 990
Coombes, L., 1584
Copeland, J., 1033 (BR)
Copello, A., 1611
Copenhaver, M., 719 (BR)
Cordero, R., 1832
Coussins, J., 126 (L)
Cox, D., 1741 (L)
Craplet, M., 1398
Croghan, E., 107
Croissant, B., 797
Cronin, M., 713 (L)
Cross, D., 689
Cuijpers, P., 1375
Cunningham, J., 561 (L), 1886 (L)
Cunningham, J.K., 479

Darke, S., 1121
Davey, M.A., 397
Davidson, R., 1372 (L)
Dawe, S., 945
Dawson, D.A., 281, 296 (C)
Day, C., 908, 930 (C)
De Jong, C.A.J., 206, 1868, 1884 (L)
De Jong, C.J., 1742 (L)
De Wet, C., 1374
Dear, K.B.G., 1280
Degenhardt, L., 459, 908, 930 (C)
Deković, M., 1464
Denzler, M., 672
Des Jarlais, D.C., 1575 (E)
Desenclos, J.-C., 1690
Detels, R., 619
DiClemente, C.C., 1046 (C)
Dietze, P., 636, 908, 930 (C)
Dijkstra, B.A.G., 1868
Dobbin, M., 197
Dolan, K.A., 820
Domingo-Salvany, A., 981
Domke, I., 1477
Donmall, M.C., 304, 500
Donny, E.C., 1496
dos Santos, M.A.B., 489
Dowling, N., 33
Drucker, E., 416 (BR)

© 2005 Society for the Study of Addiction

AUTHOR INDEX

(BR) = Book reviewer; (C) = commentary; (E) = editorial; (L) = letter to the editor; (S) = supplement.

Abbott, M., 1233 (C)
Abdullah, A.S.M., 1731
Abroms, L., 852
Ackermann, K., 797
Acosta, M.C., 550
d'Acremont, M., 1302
Adams, C., 12 (S2), 19 (S2), 28 (S2)
Ádány, R., 536
Agrawal, A., 1709
Alati, R., 643, 872 (L)
Allen, D., 1584
Allsop, S., 417 (BR), 1071 (C)
Al-Tayyib, A., 1432
Alvarez, F.J., 1373
Amass, L., 1090
Ameratunga, S., 605
Amundsen, E.J., 1453
Andersen, M.R., 379
Anderson, P., 1070 (C), 1751 (E)
Anglin, M.D., 1131
Angrist, B., 32 (S1)
Annon, J., 1131
Annon, J.J., 1090
Anstey, K.J., 1280, 1291
Anzai, Y., 19, 30 (C)
Armstrong, M.A., 30 (C)
Asbridge, M., 1340
Aveyard, P., 107

Babcock, D., 1090
Babor, T.F., 3 (E), 579 (E), 581 (E)
Baca, C.T., 1823
Bachman, J.G., 512
Bailey, P., 1 (S2)
Baker, A., 367
Baker, S., 32 (S1), 43 (S1)
Bammer, G., 636
Banbery, J., 1860
Barrio, G., 981
Barrowclough, C., 304, 500
Bauld, L., 12 (S2), 19 (S2), 28 (S2), 36 (S2), 46 (S2), 59 (S2)
Bearn, J., 495, 1374
Bechara, A., 1302
Beck, J.C., 731 (E)
Bellés, A., 1166
Benegal, V., 1051
Bennett, J., 1370 (L)
Beranuy, M., 1166
Berger, P., 68 (S1)
Berger, S.P., 58 (S1)
Berglund, M., 742, 1376
Berlin, I., 247
Bernards, S., 755
Bigelow, G.E., 1496
Bischof, G., 405
Blanken, P., 89
Blaszczynski, A., 566 (BR), 1230 (C)
Bloch, D.A., 1 (S1), 12 (S1), 58 (S1), 68 (S1), 91 (S1), 102 (S1)
Bloomfield, K., 1770
Blows, S., 605
Bobak, M., 883 (E)
Bobova, L., 953
Bond, J., 1840
Bor, W., 643, 872 (L)
Bot, S.M., 1270
Boudreau, B., 525
Brady, M., 1030 (BR)
Brandon, K.O., 439 (C)
Brandon, T.H., 439 (C)
Brasser, S.M., 1496
Braunstein, D., 43 (S1)
Brearley, R., 1860
Breland, A.B., 550
Brennan, P.L., 777
Bricker, J.B., 379
Brigham, G., 1090
van den Brink, W., 89
Brucks, M., 1537
Brugal, M.T., 981
Brunelle, E., 1377
Buchan, B., 1090
Buchhalter, A.R., 550
Bucholz, K.K., 1709
Burns, L., 787
Butler, C., 1175

Cacciola, J., 447
Camacho, L.A.B., 489
Carlin, J.B., 1518
Carlini, E.A., 897
Carpenter, C.M., 837
Carpenter, M.J., 257 (L), 1074
Carpentier, C., 884 (E), 1560
Carpentier, P.J., 1868
Carr, V.J., 367
Carroll, K.M., 267 (E)
Casadonte, P., 43 (S1)
Casswell, S., 258 (L), 971, 1069 (C)
Caulkins, J.P., 928 (C)
Chaloupka, F., 1876
Chaloupka, F.J., 1394 (E)
Chapman, S., 701
Charnaud, B., 1741 (L)
Chau, K.V., 1003
Cheater, F., 12 (S2)
Chen, H., 737
Chen, R., 852
Cheng, K.K., 107
Cherpitel, C.J., 1840
Chesterman, J., 36 (S2), 46 (S2), 59 (S2)
Chikritzhs, T., 1625, 1885 (L)
Chou, P.S., 281, 296 (C)
Choudhary, I., 990
Christensen, H., 1280, 1291
Ciraulo, A.M., 12 (S1), 23 (S1)
Ciraulo, D., 91 (S1)
Ciraulo, D.A., 12 (S1), 23 (S1), 102 (S1)
Claire, M., 367
Clapp, J.D., 327
Clark, N.C., 197
Clough, A.R., 346
Coffey, C., 1518
Cohen, M.H., 990
Coleman, F.S., 68 (S1)
Coleman, T., 12 (S2), 19 (S2), 28 (S2), 70 (S2), 84 (S2)
Collins, L., 459, 908, 930 (C)
Collins, R.L., 235
Colmant, M., 1302
Conger, R.D., 441 (C)
Connolly, G.N., 837
Connor, J., 605
Conroy, E., 908
Constable, P., 367
Cook, C.C.H., 1555 (L)
Cook, J.A., 990
Coombes, L., 1584
Copeland, J., 1033 (BR)
Copello, A., 1611
Copenhaver, M., 719 (BR)
Cordero, R., 1832
Coussins, J., 126 (L)
Cox, D., 1741 (L)
Craplet, M., 1398
Croghan, E., 107
Croissant, B., 797
Cronin, M., 713 (L)
Cross, D., 689
Cuijpers, P., 1375
Cunningham, J., 561 (L), 1886 (L)
Cunningham, J.K., 479

Darke, S., 1121
Davey, M.A., 397
Davidson, R., 1372 (L)
Dawe, S., 945
Dawson, D.A., 281, 296 (C)
Day, C., 908, 930 (C)
De Jong, C.A.J., 206, 1868, 1884 (L)
De Jong, C.J., 1742 (L)
De Wet, C., 1374
Dear, K.B.G., 1280
Degenhardt, L., 459, 908, 930 (C)
Deković, M., 1464
Denzler, M., 672
Des Jarlais, D.C., 1575 (E)
Desenclos, J.-C., 1690
Detels, R., 619
DiClemente, C.C., 1046 (C)
Dietze, P., 636, 908, 930 (C)
Dijkstra, B.A.G., 1868
Dobbin, M., 197
Dolan, K.A., 820
Domingo-Salvany, A., 981
Domke, I., 1477
Donmall, M.C., 304, 500
Donny, E.C., 1496
dos Santos, M.A.B., 489
Dowling, N., 33
Drucker, E., 416 (BR)

© 2005 Society for the Study of Addiction

Drummond, C., 128 (L)
Du, W., 626

Earleywine, M., 714 (L)
Ebner, N., 1101
Eder, H., 1101
Edwards, G., 6 (E), 145, 581 (E), 1891 (BR)
Eggleston, E., 1432
Eissenberg, T., 550
Elkashef, A., 1 (S1), 12 (S1), 58 (S1), 68 (S1), 91 (S1), 102 (S1)
Ellickson, P.L., 235
Emery, S., 1875
Emmanuelli, J., 1690
van der Ende, J., 612
Engels, R.C.M.E., 1270, 1464, 862
Epstein, D.H., 829
Erickson, D.J., 335
Ertl, M., 1027 (L)
Etter, J.-F., 1041 (C)
Evans, S.E., 550

Falba, T., 1330
Fargo, S., 953
Fendrich, M., 143 (E)
Ferdinand, R.F., 612
Ferguson, J., 12 (S2), 19 (S2), 28 (S2), 36 (S2), 46 (S2), 59 (S2)
Fergusson, D.M., 354, 577 (E), 715 (L)
Fiellin, D.A., 150
Fink, A., 731 (E)
Finn, P.R., 953
Finnegan, O., 1860
Finney, J.W., 293 (C), 1249
Finnigan, F., 51, 1680
Firth, A.Y., 46
Fischer, G., 1031 (BR), 1101
Flay, B., 1875
Flor, H., 227
Förster, J., 672
Forman, R., 447
Forman, R.F., 216
Foxcroft, D., 1066
Francis, N., 1175
Frank, R.G., 1240
Freeman, D., 1537
French, M.T., 60
Friedman, R.S., 672
Fry, C., 636
Fry, C.L., 197
Fudala, P.J., 150
de la Fuente, L., 981

Gallo, W.T., 1330
Ganapathi, L., 1432
George, S., 255
Gerstein, D.R., 133 (BR)
Giacomuzzi, S.M., 1027 (L)
Giesbrecht, N., 1563 (BR)
Gil, A.G., 1358
Gilpin, E.A., 117
Glover, E.D., 1720
Godfrey, C., 70 (S2)
Goisset, P., 1377
Goldsmith, R.J., 58 (S1), 68 (S1)
González-Saiz, F., 1373
Gossop, M., 922 (C)
Gourgou, S., 1546
Grøholt, B., 79
Grønbæk, M., 1445
de Graaf, R., 963
Graham, K., 755, 933
Grant, B.F., 281, 296 (C)
Grant, K.J., 1823
Grant, M.D., 1352
Grant, T., 367
Gray, N., 575 (E)
Greenblatt, D.J., 23 (S1)
Greenblatt, R.M., 990
Griffin, C., 107
Griffiths, P., 884 (E), 1560
Grittner, U., 1771
Grotto, I., 1021
Grüsser, S.M., 227
Grunert, V.P., 1477
Günther, V., 1027 (L)
Guardiola, E., 1166

Haaser, W., 1027 (L)
Haerpfer, C.W., 1647
Hajek, P., 299
Hall, M., 689
Hall, S., 1423
Hall, W., 459, 581 (E), 908, 930 (C)
Hambarsoomians, K., 235
Hamilton, G., 689
Hanak, C., 1302
Hand, D., 525
Hao, W., 737, 926 (C), 1840
Hapke, U., 405
Harakeh, Z., 862
Harrer, J., 1090
Harrer, J.M., 58 (S1), 68 (S1)
Hasin, D., 295 (C)
Hatch, J.P., 159
Havermans, R.C., 387
Haynie, D.L., 852
Heath, A.C., 1510, 1709
Heather, N., 945, 1557 (L)
Heilig, M., 1813
Helander, A., 1680
Heller, R.F., 500
Hendriks, V.M., 89
Henningfield, J.E., 735 (E)
Henquet, C., 874 (L)
Herd, D., 1258
Herzog, T.A., 1040 (C)
Hesselbrock, M., 720 (BR)
Hickman, M., 562 (L), 1701
Higgins, K., 189
Hillhouse, M., 1090
Hitzemann, R., 43 (S1)
Ho, S.Y., 1003
Hock, B., 1477
Hodgins, D.C., 1042 (C)
Hodgson, R., 1384 (BR)
Holder, H.D., 1026 (L), 1558 (L), 1565 (BR), 1571 (E)
Holmes, T., 102 (S1)
Holmes, T.H., 91 (S1)
Holmila, M., 417 (BR), 1763
Homans, J., 626
Homel, R., 755
Hood, K., 1175
Hope, V.D., 1701
Horspool, M., 560 (L), 1028 (L)
Horst, D., 1249
Horster, S., 1477
Horton, N.J., 70
Horwood, L.J., 354, 715 (L)
van den Hout, M., 387
Huang, B., 281, 296 (C)
Hughes, J.R., 257 (L), 1074
Huizink, A., 612
Humphreys, K., 445, 565 (BR), 751 (C), 1249
Hunt, N., 1140

Ivers, R.Q., 605

Jaffe, J.H., 921 (C), 1383 (BR)
Jagsch, R., 1101
James, D., 1487
Jansen, A., 387
Jarlais, D.D., 719 (BR)
Javors, M.A., 159
Jefferis, B.J.M.H., 543
Jenkinson, R.A., 197
Jenner, L., 367
Jernigan, D., 271
Jittiwutikarn, J., 1320
John, U., 405
Johnsen, B.-H., 1412
Johnson, C., 107
Johnson, M., 327
Johnston, L.D., 512
Jolley, D., 636
Jorm, A.F., 1280, 1291
Joshi, A.A., 1249
Judge, K., 36 (S2), 46 (S2), 59 (S2)

Kaldor, J., 820
Kampman, K., 91 (S1)
Kampman, K.M., 102 (S1)
Kapadia, F., 990
Kaper, J., 1012
Kaskutas, L.A., 60, 1637
Kay-Lambkin, F., 367
Keen, J., 560 (L), 1028 (L)
Kemp, J., 447
Kiefer, F., 1891 (BR)
King, L.A., 884 (E), 1560
Kirk, K.M., 1510
Kivimäki, M., 1150
Kloska, D.D., 512
Knapp, C., 23 (S1)
Knapp, C.M., 12 (S1)
Knibbe, R.A., 1270
Knight, J.R., 96
Knipschild, P., 317, 1392 (E)

© 2005 Society for the Study of Addiction

Kochba, I., 1021
Koeter, M.W.J., 89
Kopp, M., 1027 (L)
Koslo, R., 1720
Kovacs, A., 626, 990
Koval, J.J., 933
Kozlowski, T.L., 1352
Krabbe, P.F.M., 206, 1868, 1884 (L)
Kraigher, D., 1101
Kramer, F., 626
Kramer, S., 1770
Kreiss, Y., 1021
Krejci, J., 1090
Kunøe, N., 1027 (L)
Kuriyama, S., 19
Kvale, G., 1412
Kypri, K., 713 (L)

Längle, G., 797
Lagadec, G., 1377
Laheij, R.J., 1884 (L)
Laheij, R.J.F., 206
Lai, M.K., 1003
Lam, T.H., 1003
Lam, T.-H., 1731
Lamb, R.J., 159
Lan, H.P., 619
Lançon, C., 1377
Landen, M.G., 176
Lane, C., 1175
Lange, J.E., 327
Laobhripatr, S., 1320
Larson, M.J., 70
Lathrop, S.L., 176
Latkin, C.A., 397
Lawlor, D.A., 643, 872 (L)
Lawrence, T., 107
Lee, L., 117
Lee, N.K., 367
Leiderman, D., 23 (S1), 91 (S1), 102 (S1)
Leiderman, D.B., 1 (S1), 12 (S1), 58 (S1), 68 (S1)
Leon, D.A., 1205 (E)
Leonard, K.E., 422 (E)
Levy, D.T., 1526
Lewin, T.J., 367
Limmer, C., 1477
Ling, W., 78 (S1), 1090
Lingford-Hughes, A.R., 1889 (BR)
Linna, A., 1150
Lintzeris, N., 1832
Liu, L.-M., 479
Lloyd-Richardson, E., 430, 443 (C)
Lobmaier, P., 1027 (L)
LoCastro, J., 1 (S1), 12 (S1), 23 (S1), 102 (S1)
Loke, A.Y., 1731
Long, H.T., 619
Longshore, D., 1131
Lopes, C.S., 489
Luciano, M., 1510
van de Luitgaarden, J., 806
Lynch, K.G., 216
Lynskey, M., 1518
Lynskey, M.T., 1709
Lyyra, A.-L., 652

McAlister, S., 189
McCabe, S.E., 96, 512
McCaffrey, D.F., 235
McCambridge, J., 414 (BR), 470, 1140, 1175
McCarthy, D.M., 672
McCrystal, P., 189
McElduff, P., 500
McFadden, M., 1110
McGregor, C., 1320
McKay, J.R., 216, 447, 1594, 1755 (E)
McKee, M., 536, 1205 (E), 1647
McLellan, A.T., 447
McNeill, A., 1 (S2), 84 (S2)
Mäkelä, P., 1851
Macdonald, S., 1840
MacLeod, J., 562 (L)
Madden, P.A.F., 1709
Majewska, D., 32 (S1), 43 (S1)
Majewska, M.D., 78 (S1)
Mak, K.H., 1003
Mak, Y.W., 1731
Mallet, A., 247
Mandel, D., 1021
Mann, K., 797
Mann, R.E., 924 (C), 1669
Manning, W.G., 1383 (BR)
Manor, O., 543
Mars, S., 415 (BR)
Marsden, J., 581 (E)
Marteau, T.M., 1423
Martin, N.G., 1510, 1709
Matzger, H., 1637
Meara, E., 1240
Medina-Mora, M.E., 1566 (BR)
Medioni, J., 247
Meeus, W., 1464
Meier, P.S., 304, 500
Merikangas, K.R., 442 (C)
Metzger, D.S., 150
Meyer, C., 405
Mezinskis, J.P., 58 (S1), 68 (S1)
Midford, R., 891, 1071 (C)
Miller, W.R., 421 (E), 567 (BR)
Mimouni, F.B., 1021
Mirken, B., 714 (L)
Mitchell, T.B., 1832
Mitcheson, L., 1140
Mitsem, M., 1412
Molde, H., 1412
Monshouwer, K., 963
Montgomery, A., 1 (S1), 32 (S1), 43 (S1), 91 (S1)
Montgomery, M.A., 12 (S1), 58 (S1), 68 (S1), 78 (S1), 102 (S1)
Moodie, C., 51
Moos, R.H., 595, 777
Morgan, M., 1487
Morgenstern, J., 216
Mortensen, L.H., 1445
Moselhy, H., 255
Mosher, J.F., 129 (L), 1203 (E)
Moskalewicz, J., 1780
Moyer, A., 752 (C)
Muir, J., 1090
Mumford, E., 1526
Munné, M.I., 1790
Munro, G., 716 (L)
Mwesigye, S.-E., 1110

Najman, J.M., 643, 872 (L)
Neale, J., 168, 1584
Negrete, J.C., 133 (BR)
Nemtsov, A., 146
Nestor, L., 1832
Niaura, R., 430, 443 (C), 1720
Nides, M., 1720
Nikolayev, L., 1526
Nikolopoulou, G.B., 626
Nishino, Y., 19
Noël, X., 1302
Norström, T., 767
Norton, R., 605
Novak, S., 430
Nowicki, M.J., 626

O'Brien, C.P., 1035 (E)
O'Callaghan, M., 643, 872 (L)
O'Connor, R.J., 1352
O'Malley, P.M., 512
O'Neill, K., 787
Obot, I.S., 1210 (E)
Ohkubo, T., 19
Ohmori, K., 19
de Olalla, P.G., 981
Oliver, P., 560 (L), 1028 (L)
Olsen, N.D.L., 126 (L)
Orford, J., 1219, 1235 (C), 1611
Orr, D., 1090
Osgood, D.W., 755

Paljärvi, T., 1851
Pallesen, S., 1412
Parrott, S., 70 (S2)
Parry, C.D.H., 426
Pascal, R., 1625, 1885 (L)
Passos, S.R.L., 489
Paterson, S., 1833
Patton, G.C., 1518
Pelc, I., 1302
Percy, A., 189
Perez, R.L., 721 (BR)
Petersen, K.U., 1310
Peterson, A.V., Jr., 379
Petry, N.M., 1183
Pettinati, H.M., 216
Pierce, J.P., 117
Pietrzak, R.H., 1183
Pilsz, W., 1027 (L)
Piquet, J.M., 1377
Pitkänen, T., 652
Podschus, J., 227
Pohlman, S., 367
Poikolainen, K., 1150, 1851

© 2005 Society for the Study of Addiction

Pointer, S., 908, 930 (C)
Pomerleau, J., 1647
Ponicki, W., 1158
Poulin, C., 525
Pound, E., 12 (S2), 19 (S2), 28 (S2), 70 (S2)
Power, C., 543
Poznyak, V., 1840
Preston, K.L., 829
Primorac, A., 1101
Puig, R., 981
Pulkkinen, L., 652
Purcell, J., 755

Raabe, A., 227
Rabczenko, D., 1779
Raistrick, D., 1212, 1860
Raitasalo, K., 1763
Rajan, K.B., 379
Rao, U., 1003
Raw, M., 1 (S2), 84 (S2)
Rawson, R.A., 1131, 78 (S1)
van Ree, J.M., 89
Reed, L., 1374
Reed, L.J., 495
Rehm, J., 1840, 28 (C), 871 (L)
Reiber, C., 78 (S1)
Reid, M., 1090
Reid, M.S., 32 (S1), 43 (S1), 91 (S1), 102 (S1)
Reilly, J.L., 971
Rende, R., 430, 443 (C)
Resnicow, K., 689
Reuter, P., 459, 925 (C)
Rhodes, W., 564 (BR)
Rickert, M.E., 953
Ridder, E.M., 354, 715 (L)
Riemer, Y., 1027 (L)
Rönnberg, S., 1232 (C)
Robbins, B., 1720
Robertson, M., 168
Robinson, J., 32 (S1), 43 (S1)
Rodgers, B., 1280, 1291
Rogers, S.M., 1432
Rollnick, S., 1175
Roman, A.M., 1432
Romand, R., 1546
Room, R., 579 (E), 729 (E), 888, 1072 (C), 1226 (C), 1396, 1563 (BR), 1800, 1803
Rose, R., 1647
Ross, J., 1121
Rossow, I., 29 (C), 79, 1453
Rotily, M., 1377
Rotman, D., 1647
Rotrosen, J., 23 (S1), 32 (S1), 43 (S1), 91 (S1)
Ruan, W.J., 281, 296 (C)
Rumpf, H.-J., 405
Rush, B.R., 1669
Russell, C., 327

Sánchez-Carbonell, X., 1166
Sárváry, A., 536
Saffer, H., 1875
Saitz, R., 70
Salili, F., 1003
Samarasinghe, D., 131 (BR)
Samet, J.H., 70
Sancho-Garnier, H., 1546
Sanfilipo, M., 43 (S1)
Santor, D., 525
Santora, P.B., 735 (E)
Sarid-Segal, O., 12 (S1), 23 (S1)
Saunders, J.B., 367
Sawyer, S.M., 1518
Sayette, M., 1720
Schäfer, D.R., 797
van Schayck, C.P., 1012
Schiemann, U., 1477
Schmittner, J., 829
Schmoldt, A., 1310
Scholte, R.H.J., 862
Schroeder, J.R., 829
Schulenberg, J.E., 512
Schulze, D., 1680
Schutte, K.K., 777
Schwartz, M., 32 (S1), 1477
Selten, J.-P., 612
Seymour, R.B., 1745
Shadel, W., 1720
Shaffer, H.J., 1227 (C)
Shah, N., 176
Shearer, J., 820
Shelanski, M., 1720
Shepard, D.S., 216
Shiffman, S., 682, 1720
Shillington, A., 327
Shochat, T., 1021
Shoptaw, S., 1 (S1), 78 (S1), 91 (S1), 102 (S1), 1090
Simons-Morton, B., 852
Sindelar, J.L., 1330
Singal, B.M., 58 (S1), 68 (S1)
Skinner, W., 1566 (BR)
Skog, O.-J., 767
Skurtveit, S., 1453
Slomkowski, C., 430, 443 (C)
Smallwood, J., 1680
Smart, R.G., 132 (BR), 1669
Smit, F., 963
Smith, D., 33
Smith, G.D., 562 (L)
Smith, N., 1558
Smithson, M., 1110
Smulders, F.T.Y., 806
Sobell, L.C., 294 (C)
Sobell, M.B., 294 (C)
Sohler, N., 990
Soldz, S., 733 (E)
Somoza, E., 91 (S1)
Somoza, E.C., 58 (S1), 68 (S1), 102 (S1)
Sondeijker, F., 612
Sørensen, T.I.A., 1445
Sorrentino, J., 1720
Soyka, M., 1477
Spanagel, R., 1813
Speechley, M., 933
Srisurapanont, M., 1320
Stafström, M., 1840
Stapleton, J., 299
Stead, L., 299
Stecker, G., 1477
Stefanis, N., 874 (L)
Stek, A., 626
Stewart, S.M., 1003
Stillman, F.A., 735 (E)
Stinson, F.S., 281, 296 (C)
Stitzer, M., 1196
Stitzer, M.L., 1496
Stockwell, T., 1625, 1885 (L)
Stokwiszewski, J., 1780
Strang, J., 470, 1832
Strasser, A.A., 1352
van Straten, A., 1375
Strecher, V.J., 682
Su, Z.H., 737
Sullivan, L.E., 150
Sutton, S., 1043 (C)
Suurvali, H., 1669
Szczypka, G., 1875
Szűcs, S., 536

Takahashi, K., 19
Tanner, J., 1340
Taylor, B., 871 (L)
Teesson, M., 787, 1121
Templeton, L., 1611
Teng, H.-M., 1330
Terry-McElrath, Y., 1875
Teter, C.J., 96
Thewissen, R., 387
Thistlethwaite, G., 1860
Thomas, T., 33
Thomasius, R., 1310
Thornton, M., 189
Tilling, K., 1701
Tobin, K.E., 397
Toomey, T.L., 335, 1389 (E)
Tran, T.N., 619
Trolldal, B., 662, 1158
Tsubono, Y., 19
Tsuji, I., 19
Tucker, J.A., 1385 (BR), 1573 (E)
Tumanov, S., 1647
Tunbridge, R., 269 (E)
Turner, C.F., 1432
Tyndall, M., 923 (C)

Vagg, R., 701
Vahtera, J., 1150
Vaillant, G., 134 (BR), 294 (C)
Van Cauter Victory, R.M.V., 1884 (L)
Van der Linden, M., 1302
Van Leeuwe, J., 1464
Van Os, J., 874 (L), 963
Vandenbergh, D.J., 1352
Vega, W.A., 1358
Velleman, R., 1370 (L), 1611
Verbanck, P., 1302
Verbrugge, C.A.G., 1868
Verhulst, F.C., 612

© 2005 Society for the Study of Addiction

Verstraete, A., 1032 (BR)
Vigl, A., 1027 (L)
Villarroel, M.A., 1432
Vink, J.M., 440 (C)
Virtanen, M., 1150
Vlahov, D., 990
Voas, R.B., 327
Vocci, F., 1 (S1), 102 (S1), 91 (S1)
Vogler, G.P., 1352
Vogt, F., 1423
Vollebergh, W., 963
van der Vorst, H., 1464
Vosgien, V., 1377
de Vries, H., 862

Wagena, E.J., 317, 1012, 1392 (E)
Wagenaar, A.C., 335
Wakefield, M., 1875
Wallendorf, M., 1537
Walsh, J., 1890 (BR)
Walsh, S.L., 1496
Wartberg, L., 1310
Watson, D.W., 78 (S1)
Wayne, G.F., 837
Weatherburn, D., 927 (C)
Wechsler, H., 96
Wehner, E., 953
Weingardt, K.R., 1249
Weisner, C., 7 (E), 1637
Wells, S., 933
Wessa, M., 227
West, D., 1860
West, R., 1 (E), 299, 581 (E), 682, 887, 1036 (E), 1048 (C)
de Wet, C.J., 495
White, B., 820
White, J.M., 1320
White, R., 1741 (L)
Whybrow, J., 1 (S2)
Wichstrom, L., 79
Wiers, R.W., 806
van den Wildenberg, E., 806
Wilkins, C., 971
Willemsen, M.C., 1012
Williams, G.M., 643, 872 (L)
Williamson, A., 1121
Willner, P., 1487
Wilsnack, S.C., 1760
Windsor, T.D., 1280, 1291
Winhusen, T.M., 58 (S1), 68 (S1), 102 (S1)
Winstock, A., 1140
Winter, M., 70
Witbrodt, J., 60
Wodak, A.D., 820
Wojtyniak, B., 1779
Wongtan, T., 1320
Woo, C., 32 (S1)
Wood, E., 1194 (L)
Woodward, M., 605
Woody, G., 1090
Woody, G.E., 1758 (E)
Wortley, S., 1340
Wright, C.S., 713 (L)
Wuertemberger, M., 1477

Ye, Y., 1840

Zador, D., 141 (E), 873 (L)
Zalcman, R.F., 1669
Zapletalova, P., 1310
Zeegers, M.P.A., 317
Zeichner, D., 1310
Zhang, L., 60
Zhou, J., 820
Ziedonis, D., 1090
Zimlichman, E., 1021

© 2005 Society for the Study of Addiction

SUBJECT INDEX

(BR) = book review; (C)/(Cs) = commentary/ies; (E) = editorial; (IC) = iguana column; (L)/(Ls) = letter/s; (N&N) = news & notes; (S1) & (S2) = supplements.

absinthe
Hideous Absinthe: A History of a Devil in a Bottle 564(BR)
keeping the myth alive 571(N&N)
Addiction
Addiction and its Sciences: introduction to new series 1577(E)
alcohol in the wide world: a series of commissioned editorials 145
'A good read': new editor for, but the same philosophy 1(E)
a passion for publishing: Griffith Edwards and the creation of an institution 3(E)
Addiction Biology, goes fast forward 6(E)
addiction journal(s)
in Africa: promise and challenges of 1210(E)
Association for Medical Education and Research in Substance Abuse (AMERSA), has new publisher 136(N&N)
in China 1893(N&N)
International Society of Addiction Journal Editors (ISAJE) 135(N&N)
Addiction and Life Course 1032(BR)
adolescents
cannabis use and future psychotic symptoms 354, 612, 714(Ls), 874(Ls)
intoxicants and suicidal behaviour: changes in levels and associations (1992–2002) 79
response consistency in drug use self-reports 189, 562(L)
see also under alcohol: smoking
Afghanistan, becoming new 'narcotics state' 879(N&N)
Africa
promise and challenges of addiction journal publishing in 1210(E)
South Africa: alcohol today 426
age differences 1280, 1669
age of onset
of drinking and use of alcohol in adulthood: follow-up study from age 8–42 for females and males 652
first cannabis use: does onset shift to younger ages? Findings from (1988–2003) from Dutch National School Survey on Substance Use 963
aggression *see* violence/aggression
Alcohol: No Ordinary Commodity, BMA book award 418(N&N)
alcohol
absinthe 564(BR), 571(N&N)
adolescent(s)
does advertising promote drinking? 235
drinking level and adult binge drinking in national birth cohort 543
drinking patterns among, with immigrant and Norwegian backgrounds 1453
drinking patterns, drinking contexts and alcohol-related aggression among late, and young adult drinkers 933
-specific socialization in 1464
age of onset of drinking and use of alcohol in adulthood: follow-up study from age 42 for females and males 652
and amphetamine, excessive consumption and dependence are associated with parallel increases in subjective ratings of both 'wanting' and 'liking' 1487
in Argentina, economic crisis in 1790
in Australia 346, 720(BR), 891, 1571(E), 1625, 1885(L)
bar staff, role in preventing and managing aggression 729(E), 755
and cannabis, special issue of *Alcohol and Alcoholism* 420(N&N)
carbohydrate-deficient transferrin, γ-glutamyltransferase and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic abuse, validity of 1477
in China 737
and cirrhosis 536, 1669
college students, use among 269(E), 327, 713(L)
in Commonwealth of Independent States 1647
Controlling Your Drinking: Tools To Make Moderation Work For You 1384(BR)
and coronary heart disease risk 1150
depression and anxiety, is there a 'J-shaped' curve in association between? 643, 871(Ls)
drink driving *see* driving under the influence (DUI)
drinking volume and patterns 883(E)
expectancies
effects on drinking behaviour in peer groups 1270
negative, are associated with less drinking in non-impulsive versus impulsive subjects 953
family members of relatives with, drug and gambling problems: set of standardized questionnaires for assessing stress, coping and strain 1611
in France 1398
gender differences 1760, 1763, 1779, 1800(commentaries)
in Germany 1770
ideology, drinking patterns as 1803
in India 1051, 1892(N&N)
injury
among emergency department patients, cross-national study 1840
drinking patterns and fatal.: Finnish men 1851
intelligence in relation to later beverage preference and intake 1445
Jellinek Memorial Fund awards 571(N&N), 1198(N&N)
medical care utilization and costs in men: 4-year observation of National Health Insurance beneficiaries in Japan 19, 28(Cs)
Message in a Bottle. The Making of Fetal Alcohol Syndrome 1030(BR)
and pain management 731(E), 777
PATH Through Life Project 1280, 1291
prohibition and American temperance movement, resource for students of 723(N&N)
in public health, negotiating the place of 1396
in rap song lyrics 1203(E), 1258
reasons for drinking less and their relationship to sustained remission from problem drinking 1637, 1886(L)
-related cognitions in young heavy drinkers 806
in Russia 146
self-administered alcohol-induced 'hangover' in a naturalistic setting, effects on psychomotor and cognitive performance and subjective state 1680
sexual attraction, automatic effects of cues on 672
single screening question to identify risk drinkers, new guide recommends 1568(N&N)
social change and gendered drinking symposium 1760, 1800(commentaries)
in South Africa 426
Tequila: A Natural and Cultural History 1566(BR)
'two worlds of alcohol problems': when behaviour change succeeds,

© 2005 Society for the Study of Addiction

Finding common ground in 1573(E)
in United Kingdom 1212(E)
and violence 422(E), 729(E), 755, 933
WHO 579(E), 1751(E)
in the wide world: a series of commissioned editorials for *Addiction* 145
and young people today (USA) 271
youth access to, preventing 335
Alcohol Craving Questionnaire (ACQ), revised version 227
alcohol dependency
Chaucer Clinic 723(IC)
cognitive biases toward alcohol-related words and executive deficits in polysubstance abusers with 1302
conduct disorder and early-onset,: negative alcohol expectancies are associated with less drinking in non-impulsive versus impulsive subjects 953
Drugs for Relapse Prevention of Alcoholism 1889(BR)
influence of psychiatric morbidity in representative survey on treatment utilization and natural recovery 405
long-term course of, 5, 10 and 16 years after treatment 797
recovery from, DSM-IV 281, 293(Cs)
This Strange Illness: Alcoholism and Bill W. 719(BR)
see also alcohol intervention/treatment
alcohol industry
Alcohol Education and Research Council (AERC) and Portman Group 126(Ls), 581(E), 1370(L), 1555(Ls)
Puppet Interventions 264(N&N)
alcohol intervention/treatment
extended 1594
impact of comorbid anxiety and depression on outcomes 787
level of impaired control predicts outcome of moderation-oriented 945
outcome studies. Prevalence and predictors of research participant eligibility criteria, (1970–98) 1249
psychological, national conference, Scotland 1199(N&N)
see also alcohol dependency
alcohol marketing
does advertising promote adolescent drinking? 235
price elasticities in control and license states, US (1982–99) 1158
privatization of retail sales, effect on consumption and traffic accidents, Canada 662
Saturday opening of retail shops in Sweden 767, 1026(L)
TV advertising is not in interests of public health 258(L)
alcoholic milk case (*Moo Joose*), establishment of archive 1889(BR)
alcolock (breath-activated alcohol ignition lock), implementation in European Union 136(N&N)
alliance *see* therapeutic alliance
American Beverage Licensees attack Mothers Against Drunk Driving 1389(E)
The American Disease: Origins of Narcotic Control 1745(BR)
amphetamine/metamphetamine
brief cognitive behavioural interventions for regular users 367
excessive alcohol consumption and dependence on, are associated with parallel increases in subjective ratings of both 'wanting' and 'liking' 1487
impacts of federal precursor chemical regulations on arrests 479
withdrawal, nature, time course and severity of 1320
see also stimulants
antisocial personality disorder associated with increase severity of gambling, medical, drug and psychiatric problems among treatment-seeking pathological gamblers 1183
anxiety *see* depression/depressive symptoms, and anxiety
Argentina, alcohol and economic crisis in 1790
Association for Medical Education and Research in Substance Abuse (AMERSA) journal has new publisher 136(N&N)
attention deficit hyperactivity disorder and substance use disorders, methylphenidate in adults with 1868
Australia
alcohol
living down the legend 891
public policy importance of Northern Territory's Living with Alcohol Program, (1992–2002) 1571(E), 1625, 1885(L)
cannabis and tobacco, associations between use in remote indigenous populations in Northern 346
correlates of regular cigarette smoking in population-based sample of twins 1709
genetics of tea and coffee drinking and preference for sources of caffeine in large community sample of twins 1510
'heroin shortage' 459, 908, 921(Cs)

bar staff, role in preventing and managing aggression 729(E), 755
borderline personality disorder, impact on 12-month outcomes for treatment of heroin dependence 1121
British Medical Association (BMA) book award, *Alcohol: No Ordinary Commodity* 418(N&N)
brain science 1577(E), 1813
addiction and drugs 263(N&N)
breath carbon monoxide as marker for cigarette smoking, cut-off levels for 159
brief interventions 421(E), 470
cognitive behavioural, for regular amphetamine users 367
Britain *see* United Kingdom (UK)
Building Blocks for Tobacco Control: A Handbook 1563(BR)
buprenorphine
diversion and injection in Melbourne, Australia 197
and lofexidine, comparison of, for community opiate detoxification 1860
–naloxone versus clonidine for opiate detoxification: findings from National Institute on Drug Abuse Clinical Trials Network 1090
rise in prescribing in England: analysis of NHS regional data (2001–03) 495, 1373(Ls)

cabergoline, hydergine and levodopa/carbidopa (CREST) 78(S1)
caffeine sources, genetics of tea and coffee drinking and preference for, in Australian twins 1510
cannabis/marijuana
alcohol and, special issue of *Alcohol and Alcoholism* 420(N&N)
-based treatment fails efficacy test (MS) 263(N&N)
and car crash injury 605
and driver risks: role of epidemiology and experimentation 577(E)
first use: does onset shift to younger ages? Findings from (1988–2003) from Dutch National School Survey on Substance Use 963
potency in Europe 884(E), 1558(Ls)
and psychotic symptoms 354, 612, 714(Ls), 874(L)
self-help materials and other services, is level of interest among users in,

© 2005 Society for the Study of Addiction

aimed at reducing problem use? 561(L)
'tinny' houses in New Zealand: implications for use and sale of, and other illicit drugs 971
tobacco and, associations between use in remote indigenous populations in Northern Australia 346
tobacco initiation and nicotine dependence, frequent use as predictor of 1518
UK law faces review 722(N&N)
celecoxib (CREST) 32(S1)
central and eastern Europe, could high level of cirrhosis be due partly to quality of alcohol consumed? 536
Chaucer Clinic (alcoholism) 723(IC)
Chilling Out: The cultural politics of substance consumption, youth and drug policy 131(BR)
China 1731
alcohol today 737
bans foreign investment in tobacco market 722(N&N)
depressive symptoms and smoking among Hong Kong Chinese adolescents 1003
The Chinese Journal of Drug Abuse Prevention and Treatment 1893(N&N)
Choice, Behavioral Economics and Addiction 564(BR)
cigarette smoking *see* smoking
cirrhosis
in central and eastern Europe, could high level be due partly to quality of alcohol consumed? 536
mortality in Ontario: effects of alcohol consumption and Alcoholics Anonymous participation 1669
see also liver diseases
clinical trial registers, need for,: case study in field of addiction 1392(E)
cocaine
capturing past 10 years of research (NIDA) 419(N&N)
estimating prevalence of crack use in London using capture–recapture with covariants 1701
-induced trichtillomania 255
inhaled, nefazodone in out-patient treatment of dependence 489
Cocaine Rapid Efficacy Screening Trial (CREST) 78–110(S1)
cabergoline, hydergine and levodopa/carbidopa 78(S1)
celecoxib 32(S1)
lessons learned 102(S1)
nefazodone 23(S1)
paradigm for controlled evaluation of candidate medications 1(S1)
paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine 12(S1)
reserpine, gabapentin and lamotrigine 58(S1)
tiagabine, sertraline and donepezil 68(S1)
coenzyme Q10/L-carnitine, olanzapine, valproate, and (CREST) 43(S1)
cognitive behavioural interventions
brief, for regular amphetamine users 367
outcome of psychological treatments of pathological gambling 1412
cognitive biases toward alcohol-related words and executive deficits in polysubstance abusers with alcoholism 1302
cognitive function, non-linear relationships between, and alcohol consumption PATH Through Life Project 1280
cognitive performance and subjective state, effects of self-administered alcohol-induced 'hangover' in a naturalistic setting 1680
cognitive test scores, lower, observed in alcohol abstainers are associated with demographic, personality, and biological factors: PATH Through Life Project 1291
college students
drinking 269(E), 327, 713(L)
substance use, selection and socialization effects of fraternities and sororities, US 512
see also peer groups
Commonwealth of Independent States, drinking in,–evidence from eight countries 1647
conflict of interest *see* Portman Group and AERC (alcohol research)
context-dependency of cue-elicited urge to smoke 387
controlled drinking 945
Controlling Your Drinking: Tools To Make Moderation Work For You 1384(BR)
coronary heart disease, alcohol and,–is there an unknown confounder? 1150
crack cocaine, estimating prevalence of use in London using capture–recapture with covariants 1701
craving
assessment: psychometric properties, factor structure and revised version of Alcohol Craving Questionnaire (ACQ) 227
context-dependency of cue-elicited urge to smoke 387
smoking cue-provoked, comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving 1720
CREST *see* Cocaine Rapid Efficacy Screening Trial

dance contexts, stimulants in, five-year trends in patterns of drug use, UK 1140
death *see* mortality; overdose
depression/depressive symptoms
and anxiety
comorbid, impact on alcohol treatment outcomes 787
is there a 'J-shaped' curve in association between alcohol consumption and symptoms of? 643, 871(Ls)
cocaine dependency with comorbid 23(S1)
and smoking among Hong Kong Chinese adolescents 1003
substance dependence and,: practical implications and questions 1755(E)
substance use and elevated, gender differences in association between, in general adolescent population 525
diamorphine *see* heroin; injecting drug users
diplopia, heroin and 46
donepezil, sertraline, tiagabine (CREST) 68(S1)
driving capacity of patients treated with methadone and slow-release oral morphine 1027(L)
driving under the influence (DUI)
American Beverage Licensees attack Mothers Against Drunk Driving 1389, 1389(E)
assessing value of environmental prevention programmes in reducing, among college students 269(E), 327
investigation of effect of privatization of retail sales on consumption and traffic accidents in Alberta, Canada 662
on Venice's canals 418(N&N)
drug overdose *see* overdose
drug policy
Australian 459
Chilling Out: The cultural politics of substance consumption, youth and drug policy 131(BR)
Federal Drug Control. The Evolution of Policy and Practice 1382(BR)
Hepatitis C and Injecting Drug Use: Impact, Costs and Policy Options 718(BR)
international collaborative venture 879(N&N)
Swiss 1198(N&N)

© 2005 Society for the Study of Addiction

voluntary sector and its voice in UK 137(N&N)
drug testing in the workplace 263(N&N)
Drug Testing in the Workplace (Independent Inquiry into Drug Testing at Work 1031(BR)
Drug Treatment: What Works? 416(BR)
drug use
among female sex workers in Hanoi, Vietnam 619
deterioration over time in effect of motivational interviewing in reducing 470
extended interventions for alcohol and, disorders 1594
family members of relatives with alcohol, and gambling problems: standardized questionnaires for assessing stress, coping and strain 1611
HCV viremia is associated with, in young HIV-1 and HCV coinfected pregnant and non-pregnant women 626
predicting early therapeutic alliance in treatment of 500
reducing bias in telephone survey estimates of prevalence of 1432
Understanding Drugs and Behaviour 1030(BR)
Drug Use and Cultural Contexts 'Beyond the West' 131(BR)
Drugs and Public Policy Project 879(N&N)
Drugs for Relapse Prevention of Alcoholism 1889(BR)

economic crisis in Argentina, alcohol and,: recent findings 1790
ecstasy (MDMA)
mental disorders in current and former heavy users 1310
see also stimulants
emergency department patients, alcohol-related injury among,: cross-national study 1840
England
buprenorphine rise in prescribing in,: analysis of NHS regional data (2001–03) 495, 1373(Ls)
smoking cessation, national treatment strategy 1–70(S2)
see also United Kingdom (UK)
ethno-specific patterns
of adolescent tobacco use and mediating role of acculturation, peer smoking, and sibling smoking 1340
see also entries beginning immigrant; indigenous
Europe
cannabis potency in 884(E), 1558(Ls)
see also specific countries and regions
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), standard profiles of treatment facilities 1568(N&N)
European Union scientific production on alcohol and drug misuse (1976–2000) 1166
extended interventions for alcohol and drug use disorders. Is there a case for? 1594

family members of relatives with alcohol, drug and gambling problems: set of standardized questionnaires for assessing stress, coping and strain 1611
fatality *see* mortality; overdose
Federal Drug Control. The Evolution of Policy and Practice 1382(BR)
Federation of Drug and Alcohol Professionals (FDAP), web portal for drug and alcohol workers 571(N&N)
female sex workers in Hanoi, Vietnam. Drug use among 619
Finnish Foundation for Alcohol Studies, research news from 1892(N&N)
Finnish men, pattern of drinking and fatal injury: a population-based follow-up study of 1851
Foresight Project, UK, releases findings 1386(N&N)
former Soviet Union *see* Commonwealth of Independent States; Russia
France
alcohol today 1398
harm reduction interventions, behaviours and associated health outcomes in (1996–2003) 1690
French research studies in translation 1386(N&N)

gabapentin, reserpine, and lamotrigine (CREST) 58(S1)
gambling
antisocial personality disorder associated with increase severity of problems among treatment-seeking pathological gamblers 1183
comparison of the autonomic arousal of frequent, infrequent and non-gamblers while playing fruit machines 51
electronic gambling machines: are they the 'crack-cocaine' of? 33
family members of relatives with alcohol, drug and, problems: standardized questionnaires for assessing stress, coping and strain 1611
outcome of psychological treatments of pathological 1412
Pathological Gambling: A Clinical Guide to Treatment 565(BR)
strategies and policies for Britain. Disabling public interest 1219, 1226(Cs)
Gambling in America: Costs and Benefits 133(BR)
gender
age of onset of drinking and use of alcohol in adulthood: follow-up study from age 8–42 for females and males 652
differences in association between substance use and elevated depressive symptoms in general adolescent population 525
differences in drinking: why do they still exist? 1763
social change and gendered drinking symposium 1760, 1800(commentaries)
-specific mortality associated with alcohol in Poland in transition 1779
see also women
general anaesthesia, in opioid antagonist detoxification treatment 206, 1742(L), 1884(L)
general practitioners' and family physicians' negative beliefs and attitudes towards discussing smoking cessation with patients 1423
genetics of tea and coffee drinking and preference for source of caffeine in large community sample of Australian twins 1510
German research institute, current projects 722(N&N)
Germany, alcohol consumption in reunited 1770

Handbook of the Medical Consequences of Alcohol and Drug Abuse 132(BR)
'hangover', effects of self-administered alcohol-induced, in a naturalistic setting 1680
harm reduction
evaluating national programmes 1575(E)
interventions, behaviours and associated health outcomes in France, (1996–2003) 1690
Over the Influence: The Harm Reduction Guide for Managing Drugs and Alcohol 415(BR)
HCV *see* hepatitis C (HCV)
health care costs 70, 1240
alcohol 19, 28(Cs)
smoking cessation 70(S2)
Helping Adolescents at Risk. Prevention of Multiple Problem Behaviours 417(BR)

© 2005 Society for the Study of Addiction

hepatitis C (HCV)
imprisoned male heroin users and methadone treatment: mortality, re-incarceration and, infection 820
viremia is associated with drug use in young HIV-I and HCV coinfected pregnant and non-pregnant women 626
Hepatitis C and Injecting Drug Use: Impact, Costs and Policy Options 718(BR)
heroin
and diplopia 46
illicit use in patients prescribed pharmaceutical heroin for the management of opioid dependence. Validation of techniques to detect 1832
impact of borderline personality disorder on 12-month outcomes for treatment of dependence 1121
impact of Federal drug law enforcement on supply, in Australia 1110, 1194(L)
imprisoned male users and methadone treatment: mortality, re-incarceration and hepatitis C infection 820
matching of treatment-resistant dependent patients to medical prescription of heroin or oral methadone treatment 89
shortage in Australia 459, 908, 921(Cs)
take-home naloxone to reduce, death 1823
see also injection drug users; methadone; morphine; opiate/opioid; overdose
Hideous Absinthe: A History of a Devil in a Bottle 564(BR)
HIV/AIDS 619, 1690
decreasing international transmission: role of expanding access to opioid agonist therapies for injection drug users 150
evaluating impact of methadone maintenance programmes on mortality due to overdose and, in cohort of heroin users, Spain 981
HCV viremia is associated with drug use in young HIV-1 and HCV coinfected pregnant and non-pregnant women 626
relationship between non-injection drug use behaviors on progression to AIDS and death in cohort of HIV seropositive women in era of highly active antiretroviral therapy use 990
The Psychiatry of AIDS. A Guide to Diagnosis and Treatment 719(BR)
horizons of treatment enterprise 445
hydergine, cabergoline, and levodopa/carbidopa (CREST) 78(S1)

iatrogenic effects of psychosocial interventions for substance use disorders: prevalence, predictors, prevention 595
ideology, drinking patterns as an 1803
Illegal Drugs, Economy, and Society in the Andes 1889(BR)
immigrant and Norwegian backgrounds, drinking patterns among adolescents with 1453
India, alcohol and public health 1051
Indian Alcohol Policy Alliance, launch of 1892(N&N)
indigenous Australians 346, 720(BR), 1571(E), 1625, 1885(L)
injection drug users
decreasing international HIV transmission: role of expanding access to opioid agonist therapies for 150
harm reduction interventions, behaviours and associated health outcomes in France, (1996–2003) 1690
Hepatitis C and Injecting Drug Use: Impact, Costs and Policy Options 718(BR)
lessons from ongoing UK injectable diamorphine shortage 1741(L)
zolpidem: intravenous misuse in drug abusers 1377(L)
see also heroin; methadone; morphine; opiate/opioid; overdose
International Center for Alcohol Policies (ICAP), latest report on alcohol education: flawed peer review process 1066, 1069(Cs)
International Society of Addiction Journal Editors (ISAJE) 135(N&N)
internet *see entries beginning* web
interviews
Joseph V. Brady 1805
Elisaldo Luiz de Araújo Carlini 897
continued importance of series 880(N&N)
Robert L. Dupont 1402
Griffith Edwards 9
Harold Holder 585
Malcolm H. Lader 1057
Shanthi Ranganathan 1578
Leland H. Towle 1215
George Vaillant 274
intimate partner violence: heavy drinking as contributing cause 422(E)
intoxicants and suicidal behaviour among adolescents: changes in levels and associations from (1992–2002) 79
Iraq, substance disorders in 1567(N&N)
Italy
driving under the influence on Venice's canals 418(N&N)
profile of treatment facilities for drug users 879(N&N)

Japan, impact of alcohol consumption upon medical care utilization and costs in men 19
Jellinek Memorial Fund awards 571(N&N), 1198(N&N)

khat use in Britain. New study of 1892(N&N)

lamotrigine, reserpine, gabapentin (CREST) 58(S1)
levo-alpha-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use 1131
levodopa/carbidopa, cabergoline, hydergine and (CREST) 78(S1)
liver diseases 1477
see also cirrhosis
Living with Alcohol Program, Australia (1992–2002) 1571(E), 1625, 1885(L)
lofexidine, comparison of buprenorphine and, for community opiate detoxification 1860

MADD *see* Mothers Against Drunk Driving
marijuana *see* cannabis/marijuana
Matters of Substance 134(BR)
menstrual cycle length during methadone maintenance 829
mental disorders
in current and former heavy ecstasy (MDMA) users 1310
see also personality disorder; psychiatric morbidity; psychosis
Message in a Bottle. The Making of Fetal Alcohol Syndrome 1030(BR)
metamphetamine *see* amphetamine/metamphetamine
methadone (maintenance)
doses of 100 mg or greater are more effective than lower doses 1496
evaluating impact of programmes on mortality due to overdose and aids in cohort of heroin users, Spain 981
levo-alpha-acetylmethadol (LAAM) versus.: treatment retention and opiate use 1131
menstrual cycle length during 829
-related overdose death, unintentional, in New Mexico (USA) and implications for surveillance 176

© 2005 Society for the Study of Addiction

and slow-release morphine
comparative study of effectiveness 1101
driving capacity of patients treated with 1027(L)
methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders 1868
Moo Joose (alcoholic milk case), establishment of archive 716(L)
morphine
slow-release, and methadone, comparative study of effectiveness 1101
sustained release, as agonist treatment. New horizons 1758(E)
see also heroin; injection drug users; methadone; opiate/opioid
mortality
associated with alcohol, gender-specific, in Poland in transition 1779
fatal injury, drinking patterns and.: population-based follow-up study of Finnish men 1851
relationship between non-injection drug use behaviors on progression to AIDS and death in cohort of HIV seropositive women in era of highly active antiretroviral therapy use 990
take-home naloxone to reduce heroin death 1823
Mothers Against Drunk Driving, American Beverage Licensees attack 1389(E)
Motivating Substance Abusers To Enter Treatment: Working With Family Members 1384(BR)
motivational interviewing
deterioration over time in effect of, in reducing drug consumption and related risk among young people 470
and incredible shrinking treatment effect 421(E)
Multisystemic Therapy and Neighbourhood Partnerships: Reducing Adolescent Violence and Substance Abuse 1564(BR)

naloxone to reduce heroin death. Take-home 1823
naltrexone, fatal opiate overdose following regimen changes in treatment 560(L), 1027(Ls)
National Institute on Alcohol Abuse and Alcoholism (NIAAA), new guide recommends single screening question to identify risk drinkers 1568(N&N)
National Institute on Drug Abuse (NIDA)
academic awards from 1567(N&N)
cocaine research, capturing past 10 years of 419(N&N)
nefazodone
CREST 23(S1)
in out-patient treatment of inhaled cocaine dependence 489
new appointments 135(N&N), 571(N&N)
nicotine
analogues: review of tobacco industry research interests 701
comparative efficacy of rapid-release, gum versus nicotine polacrilex gum in relieving cue-provoked craving 1720
patch therapy, web-based computer-tailored smoking cessation program as supplement to 682
replacement therapies, increased risk of relapse after stopping 247
nortriptyline, should it be used as first-line treatment to help smokers quit? 317
Norwegian backgrounds, drinking patterns among adolescents with immigrant and 1453

obesity, smoking habits and, in young adults 1021
olanzapine, valproate, and coenzyme Q10/L-carnitine (CREST) 43(S1)
opiate/opioid
agonist therapies for injection drug users, decreasing international HIV transmission: role of expanding access to 150
agonist treatment. Sustained release morphine as 1758(E)
antagonist detoxification treatment, general anaesthesia in 206, 1742(L), 1884(L)
buprenorphine and lofexidine, comparison of, for community detoxification 1860
buprenorphine–naloxone versus clonidine for detoxification: NIDA Clinical Trials Network 1090
dependence, validation of techniques to detect illicit heroin use in patients prescribed pharmaceutical heroin for the management of 183
detoxification: what are the goals? 1035(E)
maintenance therapy, slow-release morphine and methadone, comparative study of effectiveness 1101
The Troublesome Legacy of Commissioner Lin. The Opium Trade and Opium Suppression in Fujian Province, 1820s to 1920s 414(BR)
see also heroin; injection drug users; methadone; morphine; overdose
Over the Influence: The Harm Reduction Guide for Managing Drugs and Alcohol 415(BR)
overdose
drug, calling emergency medical services: individual, social and setting correlates 397
evaluating impact of methadone maintenance programmes on mortality due to, and in cohort of heroin users, Spain 981
fatal opiate, following regimen changes in naltrexone treatment 560(L), 1027(Ls)
non-fatal
recent life problems and among heroin users entering treatment 168
reducing, among heroin users as an all-of-society challenge 141(E)
transient changes in behaviour lead to heroin 636, 873(L)

pain management, alcohol and 731(E), 777
parent(s)
smoking cessation, does it encourage their young adult children to quit smoking? 379
rules and communiction: association with adolescent smoking 862
of young children, smoking cessation intervention in 1731
see also socialization
paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine (CREST) 12(S1)
PATH Through Life Project
lower cognitive test scores observed in alcohol abstainers are associated with demographic, personality, and biological factors 1291
non-linear relationships between cognitive function and alcohol consumption in young, middle-aged and older adults 1280
Pathological Gambling: A Clinical Guide to Treatment 565(BR)
patient(s)
characteristics and initial progress in treatment, do they moderate effectiveness of telephone-based continuing care for substance use disorders? 216
matching of treatment-resistant heroin-dependent, to medical prescription of heroin or oral methadone treatment 89
resistance (smokers), effect on practitioner behaviour 1175
peer groups
effects of expectancies on drinking behaviour in.: observations in naturalistic setting 1270

© 2005 Society for the Study of Addiction

ethno-specific patterns of adolescent tobacco use and mediating role of acculturation, and sibling smoking 1340
see also college students
pentoxifylline, paroxetine, riluzole, pramipexole and venlafaxine (CREST) 12(S1)
personality disorder
antisocial, associated with increase severity of gambling, medical, drug and psychiatric problems among treatment-seeking pathological gamblers 1183
borderline, impact on 12-month outcomes for treatment of heroin dependence 1121
personality, lower cognitive test scores observed in alcohol abstainers are associated with demographic, and biological factors: PATH Through Life Project 1291
Poland, gender-specific mortality associated with alcohol in 1779
Portman Group and AERC (alcohol research) 126(Ls), 581(E), 1370(L), 1555(Ls)
pramipexole and venlafaxine, paroxetine, pentoxifylline, riluzole (CREST) 12(S1)
pregnancy, does smoking cessation advice in, result in long-term quitters? 107
primary medical care and reductions in addiction severity 70
psychiatric morbidity
influence in alcohol-dependent subjects in representative survey on treatment utilization and natural recovery 405
see also mental disorders; personality disorder; psychosis
The Psychiatry of AIDS. A Guide to Diagnosis and Treatment 719(BR)
psychomotor and cognitive performance and subjective state. Effects of self-administered alcohol-induced 'hangover' 1680
psychosocial interventions for substance use disorders, iatrogenic effects,: prevalence, predictors, prevention 595
psychosis
cannabis use and 354, 612, 714(Ls), 874(L)
Stanley Medical Research Institute (SMRI), funding for research into schizophrenia and bipolar disorder 1199(N&N)
Substance Misuse in Psychosis–Approaches to Treatment and Service Delivery 1890(BR)
Public Health Policy on Alcohol: An International Perspective 1562(BR)
public policy importance of Northern Territory's Living with Alcohol Program, (1992–2002) 1571(E), 1625
publishing: Griffith Edwards and the creation of an institution 3(E)
Publishing Addiction Science: A Guide for the Perplexed 414(BR)

qualitative research methods within addictions 1584

rap song lyrics, alcohol use in 1203(E), 1258
recanting
rate analysis, response consistency in young adolescents' drug use self-reports 189, 562(L)
undeniable problem of, in survey research 143(E)
reimbursement for smoking cessation treatment may double abstinence rate 1012
reporting bias *see* recanting
reserpine, gabapentin and lamotrigine (CREST) 58(S1)
riluzole, paroxetine, pentoxifylline, pramipexole and venlafaxine (CREST) 12(S1)
Russia, alcohol yesterday and today 146

Saturday opening of alcohol retail shops in Sweden 767, 1026(L)
school-based harm minimization smoking intervention trial: outcome results 689
Scotland
national conference on psychological interventions in treatment of alcohol related problems 1199(N&N)
see also UK
self-help materials and other services, is level of interest among cannabis users aimed in, at reducing problem use? 561(L)
self-reported drug use *see* recanting
sertraline and donepezil, tiagabine (CREST) 68(S1)
sex workers, female, in Hanoi, Vietnam. Drug use among 619
sexual attraction, automatic effects of alcohol cues on 672
sibling(s)
effects on, smoking in adolescence: evidence of social influence from genetically informative design 430, 439(Cs)
ethno-specific patterns of adolescent tobacco use and mediating role of acculturation, peer smoking and, smoking 1340
Similarities in Animal and Human Drug-Taking Behavior 1196
SimSmoke tobacco control policy simulation model 1526
Slovenia, *Lipič, Franz Wilhelm (1834) Osnovne Značilnosti Dipsobiostatike* [facsimile edition with commentaries] 1891(BR)
slow-release morphine and methadone, comparative study of effectiveness of opioid maintenance therapy 1101
slow-release oral morphine. Driving capacity of patients treated with methadone and 1027(L)
smoking
adolescents
depressive symptoms and, among Hong Kong Chinese 1003
ethno-specific patterns of tobacco use and mediating role of acculturation, peer, and sibling 1340
how have risk factors changed with recent declines in California? 117
parental rules and communication: association with 862
psychosocial predictors during middle and high school 852
sibling effects,: evidence of social influence from genetically informative design 430, 439(Cs)
banning in taverns and restaurants–research opportunity as well as public health gain 888
context-dependency of cue-elicited urge to smoke 387
correlates of regular, in population-based sample of Australian twins 1709
cut-off levels for breath carbon monoxide as marker for 159
early experiences and status in national cross-sectional sample 1352
explaining recent trends in prevalence 1394(E)
feasibility of reduction: update 1074
habits and obesity in young adults 1021
involuntary job loss, effect on intensity and relapse 1330
long-range effects of early tobacco use. Revisiting drug progression 1358
pathways and prevention in tobacco use 733(E)
patient resistance, effect on practitioner behaviour 1175
The Price of Smoking 1383(BR)
school-based harm minimization,: outcome results 689
SimSmoke tobacco control policy simulation model 1526
tobacco and cannabis

© 2005 Society for the Study of Addiction

associations between use in remote indigenous populations in Northern Australia 346
reverse gateway? 1518
trajectories, psychosocial predictors during middle and high school 852
young children's understandings of 1537
see also smoking cessation; tobacco industry
smoking cessation
abstinence symptom suppression: role played by smoking-related stimuli that are delivered by denicotinized cigarettes 550
defining quit attempts: what difference does a day make? 257(L)
does advice in pregnancy result in long-term quitters? 107
Five-Day Plan, randomized trial for assessing 1546
general practitioners' and family physicians' negative beliefs and attitudes towards discussing, with patients 1423
national treatment strategy, England 1–84(S2)
cost-effectiveness 70(S2)
delivering services 19(S2)
effectiveness of services in reaching disadvantaged smokers 36(S2)
implementing service 12(S2)
lessons 84(S2)
one-year outcomes 59(S2)
short-term outcomes 46(S2)
targeting smokers in priority groups 28(S2)
nicotine therapies *see entries beginning* nicotine
nortriptyline, should it be used as first-line treatment? 317
outcome criteria in trials: proposal for common standard 299
parental, does it encourage their young adult children to quit smoking? 379
parents of young children, intervention in 1731
reimbursement for treatment may double abstinence rate 1012
Transtheoretical (Stages of Change) Model 1041(C)
unique forum for UK professionals (UKNSCC) 1386(N&N)
social change and gendered drinking symposium 1761, 1801(commentaries)
social transition and substance abuse 1205(E)
socialization
alcohol-specific, in adolescents' drinking behaviour 1464
college students substance use, selection and, effects of fraternities and sororities, US 512
see also parent(s); sibling(s)
South Africa, alcohol today 426
specialist nurse, role with substance misusing clients 419(N&N)
spending *see* health care costs
Stanley Medical Research Institute (SMRI), funding for research into schizophrenia and bipolar disorder 1199(N&N)
stimulants
in dance contexts in UK, five-year trends in patterns of drug use among people who use 1140
non-medical use of prescription, among US students: prevalence and correlates 96
see also amphetamine/metamphetamine; cocaine
This Strange Illness: Alcoholism and Bill W. 719(BR)
stress, coping and strain, standardized questionnaires for assessing, family members of relatives with alcohol, drug and gambling problems 1611
Substance Misuse in Psychosis–Approaches to Treatment and Service Delivery 1890(BR)
substance use/disorders
and depression, co-occurring: practical implications and questions 1755(E)
iatrogenic effects of psychosocial interventions for.: prevalence, predictors, prevention 595
in Iraq 1567(N&N)
methylphenidate in adults with attention deficit/hyperactivity disorder and 1868
social transition and 1205(E)
spending on, treatment: how much is enough? 1240
what place for women-only treatment programs? 7(E)
suicidal behaviour, intoxicants and.: changes in levels and associations from (1992–2002) 79
survey research, undeniable problem of recanting 143(E)
Sweden, Saturday opening of alcohol retail shops in 767, 1026(L)
Swedish Council for Information on Alcohol and Other Drugs, Drug Research Award 1198(N&N)
Swiss law on narcotics, Revision of 1198(N&N)

telephone audio-CASI (computer-assisted self-interviewing) 1432
telephone-based continuing care for substance use disorders? Do patient characteristics and initial progress in treatment moderate effectiveness of 216
television
alcohol advertising is not in interests of public health 258(L)
campaigns, mixed messages on tobacco: comparative exposure to public health, tobacco company- and pharmaceutical company-sponsored tobacco-related, US, (1999–2003) 1875
Tequila: A Natural and Cultural History 1566(BR)
therapeutic alliance
contribution to treatment approaches 267(E), 304
predicting early, in treatment of drug misuse 500
tiagabine, sertraline and donepezil (CREST) 68(S1)
tobacco industry
(BAT) Guildford Depository documents now online 418(N&N)
China bans foreign investment in market 722(N&N)
designing cigarettes for women 735(E), 837
nicotine analogues: review of research interests 701
and pharmaceutical company-sponsored tobacco-related television campaigns 1875
time to change attitudes to.: product regulation over five years? 575(E)
traffic accidents, investigation of effect of privatization of retail sales on consumption and, in Alberta, Canada 662
Transtheoretical (Stages of Change) Model. Putting to rest 1036(E), 1040(Cs)
Treating Alcohol and Drug Abuse 566(BR)
treatment
evaluation of, from retrospective follow-up to concurrent recovery monitoring 447
horizons of, enterprise 445
three lessons for improving, from meta-analytical study. A better widget? 742, 751(Cs), 1375(Ls)
trichtillomania, cocaine-induced 255
The Troublesome Legacy of Commissioner Lin. The Opium Trade and Opium Suppression in Fujian Province, 1820s to 1920s 414(BR)

Understanding Drugs and Behaviour 1030(BR)
Understanding Substance Addictions: Assessment and Interventions 1565(BR)
United Kingdom (UK)
alcohol today 1212(E)

© 2005 Society for the Study of Addiction

BMA book award, *Alcohol: No Ordinary Commodity* 418(N&N)
cannabis law faces review 722(N&N)
estimating prevalence of crack cocaine use in London using capture–recapture with covariants 1701
Foresight Project releases findings 1386(N&N)
gambling strategies and policies. Disabling public interest 1219, 1226(Cs)
khat use in, new study of 1892(N&N)
lessons from ongoing injectable diamorphine shortage 1741(L)
National Smoking Cessation Conference (UKNSCC) 1386(N&N)
stimulants in dance contexts, five-year trends in patterns of drug use 1140
voluntary sector and its voice in drugs policy 137(N&N)
United States (US)
alcohol and young people today 271
alcohol price elasticities in control and license states (1982–99) 1158
American Beverage Licensees attack Mothers Against Drunk Driving 1389(E)
The American Disease: Origins of Narcotic Control 1745(BR)
college student substance use, selection and socialization effects of fraternities and sororities 512
prohibition and American temperance movement, web-based resource 723(N&N)
non-medical use of prescription stimulants among, students: prevalence and correlates 96
recovery from DSM-IV alcohol dependence 281, 293(Cs)
television campaigns, mixed messages on tobacco: comparative exposure to public health, tobacco company- and pharmaceutical company-sponsored tobacco-related, (1999–2003) 1875
unintentional methadone-related overdose death in New Mexico (USA) and implications for surveillance 176
university students *see* college students

valproate, olanzapine, and coenzyme Q10/L-carnitine (CREST) 43(S1)
venlafaxine, paroxetine, pentoxifylline, riluzole, pramipexole and (CREST) 12(S1)
violence/aggression
alcohol and intimate partner.: heavy drinking as contributing cause 422(E)
assaults 767
bar staff, role in preventing and managing 729(E), 755
drinking patterns, drinking contexts and alcohol-related, among late adolescent and young adult drinkers 933
Multisystemic Therapy and Neighbourhood Partnerships: Reducing Adolescent Violence and Substance Abuse 1564(BR)
voluntary sector and its voice in UK drugs policy 137(N&N)

web portal for drug and alcohol workers, Federation of Drug and Alcohol Professionals (FDAP) 571(N&N)
web-based computer-tailored smoking cessation program as supplement to nicotine patch therapy 682
web-based resource for students of prohibition and American temperance movement 723(N&N)
women
designing cigarettes for 735(E), 837
does smoking cessation advice in pregnancy result in long-term quitters? 107
HCV viremia is associated with drug use in young HIV-1 and HCV coinfected pregnant and non-pregnant 626
menstrual cycle length during methadone maintenance 829
-only treatment programs 7(E), 60
relationship between non-injection drug use behaviors on progression to AIDS and death in cohort of HIV seropositive women in era of highly active antiretroviral therapy use 990
sex workers in Hanoi, Vietnam. Drug use among 619
see also gender
workplace drug testing 263(N&N), 1031(BR)
World Health Organization (WHO)
global action on alcohol 579(E)
monitoring of the State of the World's drinking 1751(E)

young children
smoking cessation intervention in parents of 1731
understandings of cigarette smoking 1537
youth *see* adolescents *and entries under* alcohol; smoking

zolpidem, intravenous misuse in drug abusers 1377(L)

© 2005 Society for the Study of Addiction